Tag

Pharmaceuticals

All articles tagged with #pharmaceuticals

business22 days ago•142 min saved

AstraZeneca and BMS explore $400B mega-merger, sparking pharma consolidation chatter

Reuters reports AstraZeneca and Bristol Myers Squibb held preliminary talks about a potential merger valued at about $400 billion, which would create one of the world’s largest pharma companies. The status of talks is unclear, and such a deal would face U.S. antitrust scrutiny under the Trump administration and could require divestitures. The companies’ oncology franchises are a focal point, with historical context from Bristol Myers’ Celgene deal cited in analysis.

via Investing.com|

#antitrust #astrazeneca #bristol-myers-squibb

mergers-acquisitions-and-takeovers23 days ago•12 min saved

AZN and BMY Consider $400B Merger in Pharma Tie-Up

AstraZeneca and Bristol-Myers Squibb are reportedly in talks to merge, with a combined value near $400 billion that would create one of the world's largest pharma groups; no deal terms have been disclosed and talks could stall. Such a cross-border deal would face antitrust reviews in the US, UK, and EU, with investors awaiting more detail ahead of the Q3 2026 results in late October.

via Yahoo Finance|

#astrazeneca #bristol-myers-squibb #mergers-acquisitions

business23 days ago•2 min saved

AZ and BMS weigh a near-$400bn pharmaceutical mega-merger

AstraZeneca is in talks with Bristol Myers Squibb about a potential tie-up valued at roughly $400 billion, which would create one of the world's largest drugmakers. Discussions have been ongoing and could materialize soon but may also be delayed or collapse. The deal would reinforce AstraZeneca's US-focused pivot after its NY listing, with both companies keeping comments to themselves as talks proceed.

via Financial Times|

#astrazeneca #bristol-myers-squibb #business

business28 days ago•3 min saved

GSK shifts funds to late-stage R&D, relocates HQ to Cambridge

GSK unveiled a three-year plan to reallocate resources toward its late-stage R&D and move its research HQ from Stevenage to Cambridge, aiming for 1.9 billion pounds in annual savings by 2029 at a 2.4 billion pound one-time cost. Savings will come mainly from procurement and portfolio shifts from mature products to novel therapies, with no jobs figure disclosed yet, and will fund further pipeline assets such as antibody-drug conjugates as the company counters 2028 dolutegravir patent expiry; the London HQ remains, and a 400 million pound Cambridge investment underscores tighter integration with the UK life sciences ecosystem.

via Fierce Biotech|

#business #cambridge #cost-savings

politics1 month ago•4 min saved

Trump proposes phased 100% tariffs on generic drugs starting 2028 to push U.S. production

Trump floated a plan to impose tariffs on generic drugs in a phased way: 0% for two years starting Aug 1, 2026, then 100% for one year, and 200% thereafter, meaning 100% tariffs would begin in August 2028 to push U.S. production. No formal order has been issued yet. The policy follows ongoing drug-pricing and trade actions, with exemptions for plants under construction and some trading partners; a White House spokesperson did not immediately respond.

via Politico|

#generic-drugs #pharmaceuticals #politics

health1 month ago•2 min saved

FDA recalls millions of prednisolone eye drops over potential contaminant risk

The FDA issued a Class II recall of about 2.5 million bottles of prednisolone acetate ophthalmic suspension 1% eye drops by Lupin Pharmaceuticals due to a potential foreign-substance contamination. The products—available in 5 mL, 10 mL, and 15 mL sizes—were initially recalled on June 4 and reclassified on June 30; the drops treat non-infectious eye allergies and inflammation.

via Boston 25 News|

#contamination #eye-drops #fda

health1 month ago•119 min saved

Medicare to cover select GLP-1 weight-loss drugs for $50 copay

Medicare has started covering certain GLP-1 weight-loss medications with a $50 copay, outlining which drugs are included and the eligibility criteria for beneficiaries. The policy aims to expand access to obesity treatments from manufacturers like Novo Nordisk and Eli Lilly, though coverage may depend on clinical indications and program details.

via AP News|

#glp-1-drugs #health #health-policy

health2 months ago•17 min saved

Oral GLP-1 Weight-Loss Drugs Enter a Crowded, High-Stakes Race

Pharma firms are racing to bring pill-form GLP-1 weight-loss drugs to market, with aleniglipron and elecoglipron delivering about 11–12% weight loss over 36 weeks in Phase II, thanks to absorption-enhancers or small-molecule designs, while other candidates like Roche CT-996, Ascletis ASC30, and Viking VK2735 are in development. Even if approved, competition could lower prices and expand options beyond injections like Ozempic/Wegovy.

via Gizmodo|

#glp-1s #health #obesity

business2 months ago•19 min saved

Healthcare Leaders Rally to Fresh Highs as Lilly, J&J and AbbVie Soar

Healthcare stocks outperformed the broader market as Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hit fresh 52-week highs (with Merck near highs), while biotech names like Moderna led rallies; the Health Care Select Sector SPDR ETF XLV has climbed about 3% year-to-date, signaling renewed investor interest in defensive healthcare plays amid ongoing M&A activity.

via Yahoo Finance|

#business #eli-lilly #healthcare

business2 months ago•1 min saved

Sangamo to Sell Most Assets in Bankruptcy, Lilly and Astellas Lead Bids

Sangamo Therapeutics has filed for bankruptcy and will pursue a sale of substantially all its assets. Eli Lilly and Astellas are named as stalking-horse bidders, with Lilly set to acquire Sangamo’s capsid delivery platform, zinc finger platform, Modular Integrase (MINT) platform, and the ST-506 prion disease program, while Astellas aims to buy the Fabry disease asset isaralgagene civaparvovec. Other assets, including ST-503 for chronic neuropathic pain, giroctocogene fitelparvovec for hemophilia A, and the cell therapy/Treg assets, are not included in these initial bids. Sangamo has faced years of cash strain, Pfizer exiting a key collaboration, and its stock has fallen dramatically, prompting the asset-sale process to maximize value for creditors and stakeholders.

via Fierce Biotech|

#asset-sale #bankruptcy #biotech

business2 months ago•2 min saved

Supreme Court narrows patent risk for skinny-label generics

The Supreme Court unanimously ruled Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, shielding generic manufacturers from certain patent lawsuits and paving the way for more affordable generics while overturning a lower court ruling.

via statnews.com|

#business #generic-drugs #patents

healthcare3 months ago•2 min saved

Regenxbio hits milestone in Duchenne gene therapy ahead of FDA filing

Regenxbio announced its experimental Duchenne muscular dystrophy gene therapy produced sufficient levels of a miniaturized muscle protein in a clinical trial, paving the way for an FDA submission and aiming to improve on Sarepta’s Elevidys in both efficacy and safety, amid ongoing safety concerns surrounding the competitor.

via statnews.com|

#biotechnology #clinical-trials #duchenne-muscular-dystrophy

technology3 months ago•5 min saved

Orbital pharma gains momentum as Varda teams with United Therapeutics to grow drugs in microgravity

Private space startup Varda Space Industries is expanding commercial drug production in orbit, partnering with United Therapeutics to use microgravity to improve drug crystallization and stability. The approach combines Earth‑based screening in a new 10,000‑sq‑ft lab with a plan to launch multiple autonomous satellites to test and manufacture therapies in space, aiming to shorten development times and create products valuable enough to justify reentry to Earth. This marks a notable milestone in the evolving orbital biotech economy as the cadence of launches increases and long‑term goals shift toward building a space‑based pharmaceutical business.

via Ars Technica|

#microgravity #orbital-manufacturing #pharmaceuticals

business4 months ago•2 min saved

Sun Pharma to buy Organon for $11.75B in all-cash deal, expanding global footprint

Sun Pharmaceutical Industries will acquire Organon & Co in an all-cash deal valued at $11.75 billion (including debt) at $14 per share, boosting Sun Pharma’s revenue to about $12.4 billion and expanding its footprint in the U.S. and global markets with Organon’s women’s health and biosimilars portfolio, aligning with Sun Pharma’s move into innovative medicines.

via CNBC|

#business #global-expansion #mergers-and-acquisitions

health4 months ago•22 min saved

Drug Story: How Medicines Reveal Society and Public Health

STAT’s First Opinion interview with Thomas Goetz explains Drug Story, a podcast that uses a three‑act framework—diagnosis, prescription, side effects—to explore how individual drugs illuminate broader social, economic, and policy forces shaping health, from obesity and insomnia to ivermectin repurposing. Goetz, who holds an MPH, argues medicines reflect not just biology but systemic determinants and the common good, and he plans a second season of about 30 more drugs, produced independently to broaden public understanding of health and medicine.

via statnews.com|

#drugstory #health #journalism